A PHASE IV, OPEN-LABEL SINGLE-ARM STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ANTIRETROVIRAL COMBINATION OF RILPIVIRINE AND RITONAVIRBOOSTED DARUNAVIR IN THERAPY-NAIVE HIV-1 INFECTED PATIENTS.: